Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) Stock Sees Buying Interest At Lower Level
Shares of Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) was in focus in Thursday’s trading session with a jump of about 5%.
Market Action
On Thursday, PVCT stock jumped 4.94% at $0.0578 with more than 320k shares, compared to its average volume of 328K shares. The stock has moved within a range of $0.0550 – 0.0600 after opening the trade at $0.0551.
Presentation of Updated Data from Combination Therapy Trial of PV-10® and Keytruda®
Provectus Biopharmaceuticals on October 28, 2021 announced updated response as well as immune correlative data from its ongoing Phase 1b clinical trial of cancer immunotherapy PV-10. This was in combination with Keytruda (pembrolizumab), for treating advanced cutaneous melanoma in patients.
Some of the baseline characteristics include 22 patients from which 19 were being tested for efficacy. While 68% were male, the median age was 72 years. Additionally, safety part was done for 22 patients. For PV-10, it reflected 1-2 injection-site reactions while for Keytruda, there were immune-mediated reactions of grade 1-3. However, the best response was seen for 5% with 26% objective response rate and 53% disease control rate. The durability of the response was 4.9 months median progression-free survival while the survival is 34.1 months median overall survival.
The data also showed an increase in damage-associated molecular pattern high mobility group box protein 1 being consistent with HMGB1 pattern of PV-10.
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors said that the company’smelanoma drug development program has been consistent and demonstrated PV-10’s unique and adaptive immune signaling mechanisms.
Rodrigues added that over 50 patients are treated with PV-10-Keytruda combination therapy for various melanoma indications and the data shows that cancer immunotherapy PV-10 can restore checkpoint blockade activity.
Key Quote
Dominic Rodrigues, Vice Chair of the Company’s Board of Directors, said, “Our melanoma drug development program has consistently and reproducibly shown PV-10’s unique innate and adaptive immune signaling mechanisms in single-agent and checkpoint blockade combination therapy clinical trials. To date, more than 50 patients have been treated with PV-10-Keytruda combination therapy for different melanoma indications. Current data notably demonstrate that cancer immunotherapy PV-10 can restore checkpoint blockade activity in patients who are refractory to this immunotherapy drug class.”
Traders Note
PVCT stock is trading below the 20-Day and 50-Day Moving averages of $0.0609 and $0.0620 respectively. Moreover, the stock is trading below 200-Day moving average of $0.0679. The stock is up 16% in the past 3-month.
